Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
Dose A Ker-012, Dose B Ker-012, Dose C Ker-012
Pulmonary Arterial Hypertension
Phase II
Completed
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
Jul 13, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Keros Therapeutics (KROS) have in its pipeline
KROS is currently developing the following drugs: Dose A Ker-012, Dose B Ker-012, Dose C Ker-012. These drug candidates are in various stages of clinical development as the company works toward FDA approval.